Nelson, L. M.
DiBenedetti, D.
Pariser, D. M.
Glaser, D. A.
Hebert, A. A.
Hofland, H.
Drew, J.
Ingolia, D.
Gillard, K. K.
Fehnel, S.
Funding for this research was provided by:
Dermira, Inc. (N/A)
Article History
Received: 3 August 2018
Accepted: 15 August 2019
First Online: 5 September 2019
Ethics approval and consent to participate
: Source data were from two phase 3 clinical trials that were reviewed and approved by local institutional review boards and independent ethics committees on May 13, 2015.
: Not applicable.
: LN, DD, and SF: Employee of RTI Health Solutions. DMP: Consultant (honoraria): Brickell Biotech, Inc.; Biofrontera AG; Celgene; Dermira, Inc.; DUSA Pharmaceuticals, Inc.; LEO Pharma; Novartis; Promius Pharma, LLC; Regeneron Pharmaceuticals, Inc.; Sanofi; TheraVida, Inc.; Valeant Pharmaceuticals International, Inc. Advisory board (honoraria): Pfizer, Inc. Investigator (grants/research funding): Abbott Laboratories; Amgen, Inc.; Brickell Biotech, Inc.; Celgene; Dermavant Sciences; Eli Lilly and Company; LEO Pharma; Merck & Co, Inc.; Novartis; Novo Nordisk A/S; Ortho Dermatologics; Peplin, Inc.; Photocure ASA; Promius Pharma, LLC; Regeneron Pharmaceuticals, Inc.; Stiefel Laboratories; Valeant Pharmaceuticals International, Inc. Investigator (honoraria): LEO Pharma; Pfizer, Inc. DAG: Consultant and investigator: Dermira, Inc. AAH: Investigator (research funding): Dermira, Inc. (paid to the UTHealth McGovern Medical School, Houston). Advisory board (honoraria): Dermira, Inc. Research funding (all monies paid to the UTHealth McGovern Medical School, Houston): Allergan, Plc.; Amgen, Inc.; Cassiopea; Celgene; Dermavant Sciences; Eli Lilly and Company; Galderma S.A.; GSK, Plc.; LEO Pharma; Mayne Pharma; Medimetriks Pharmaceuticals; Novan, Inc.; Promius Pharma, LLC; Vanda Pharmaceuticals. Honoraria: Amgen; GSK, Plc.; Pfizer, Inc.; Valeant Pharmaceutics International, Inc. HH, JD, KKG, and DI: Employee and stockholder of Dermira, Inc.